DrugPatentWatch Database Preview
XERAVA Drug Profile
» See Plans and Pricing
When do Xerava patents expire, and what generic alternatives are available?
Xerava is a drug marketed by Tetraphase Pharms and is included in one NDA. There are two patents protecting this drug.
This drug has seventy patent family members in thirty countries.
The generic ingredient in XERAVA is eravacycline dihydrochloride. Additional details are available on the eravacycline dihydrochloride profile page.
US ANDA Litigation and Generic Entry Outlook for Xerava
Xerava will be eligible for patent challenges on August 27, 2022. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 28, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for XERAVA
| International Patents: | 70 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for XERAVA |
| DailyMed Link: | XERAVA at DailyMed |
Generic Entry Opportunity Date for XERAVA
Generic Entry Date for XERAVA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for XERAVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XERAVA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 603568 | Start Trial |
| Cyprus | 1114689 | Start Trial |
| Taiwan | I585077 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for XERAVA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2323972 | 19C1012 | France | Start Trial | PRODUCT NAME: ERAVACYCLINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/18/1312 20180924 |
| 2323972 | 2019010 | Norway | Start Trial | PRODUCT NAME: ERAVASYKLIN ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV; REG. NO/DATE: EU/1/18/1312 20181025 |
| 2323972 | PA2019009,C2323972 | Lithuania | Start Trial | PRODUCT NAME: ERAVACIKLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1312 C(2018)6231 20180920 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
